ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Institut Curie at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Institut Curie takes part in 26 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8042. Its program connects cancer biomarkers and treatment strategies across breast, lung and other cancers. It examines circulating tumour DNA for detecting relapse in HPV-related pelvic cancer and treatment approaches for metastatic uveal melanoma.

OrganizationESMO 2026 Attendance
Institut Curie
Paris, France
Cancer centre & hospitalExhibitor
Private non-profit cancer centre in Paris, France, combining a research centre with hospital sites.
Booth
Exhibiting at Booth 8042
Satellite
Fri Oct 23
09:50–10:15
HR-Positive Metastatic Breast Cancer: Advances in First-Line Management and Sequencing
Medscape Global Oncology - Redrawing the Breast Cancer Roadmap: Advancing Novel Therapies Into First-Line and Early Disease Settings
Breast cancer
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Clinical utility of HPV circulating tumor DNA in anal cancer: Real-world data from a French high-volume center
ePoster session 19
Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
French recommendations on multigene panel testing in pancreatic ductal adenocarcinoma
ePoster session 17
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
HER2 IHC expression across multiple solid tumor types: Insights from the ESPERANZA Programme
ePoster session 23
Biomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Tebentafusp discontinuation after sustained disease control in metastatic uveal melanoma (mUM): A single-center ambispective observational study
ePoster session 11
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
ctDNA and survival outcomes in first-line ICI-treated metastatic NSCLC-interim analysis
ePoster session 13
Lung & thoracic cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
An in-depth multistate analysis of a national multidisciplinary tumour board (MTB) for patients with cancer of unknown primary
Friday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
15:15–16:00
Comprehensive genomic profiling in lacrimal duct carcinoma reveals HER2-driven biology and emerging therapeutic targets
Friday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Integrated clinical and transcriptomic biomarkers predict survival and immune checkpoint inhibitor response in cancers of unknown primary
Friday Poster Display session 2
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
MTAP loss and HPV status in head and neck squamous cell carcinoma (HNSCC): A genomic landscape study
Friday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Satellite
Fri Oct 23
18:15–18:20
Welcome
Servier - Toward a New Paradigm in Metastatic Uveal Melanoma: From Biological Insight to Practical Treatment Strategies
Melanoma & skin cancers
Satellite
Fri Oct 23
19:15–19:40
Interactive Case and Panel Discussion: Applying Evidence to Practice
Servier - Toward a New Paradigm in Metastatic Uveal Melanoma: From Biological Insight to Practical Treatment Strategies · with Thomas Jefferson University Hospital
Melanoma & skin cancers
Poster
Sat Oct 24
12:00–12:45
Darovasertib with crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma (OptimUM-02): A subgroup analysis
Saturday Poster Display session 4
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
PLUME: Overall survival results from a phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM)
Saturday Poster Display session 4
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Profiles of patients with metastatic cancer in progression based on their prognostic information preference
Saturday Poster Display session 5
Nursing & supportive care
Satellite
Sat Oct 24
13:05–13:35
Maximizing 1L outcomes in HR+ mBC
AstraZeneca - Advancing 1L Breast Cancer Care Across Subtypes: Recent Developments and Future Directions
Breast cancer
Talk
Sat Oct 24
17:00–17:15
How to monitor biomarkers and ctDNA
Novel concepts for metastatic breast cancer: Looking to the future
Breast cancerBiomarkers & precision oncology
Satellite
Sun Oct 25
13:20–14:05
Neoadjuvant vs Perioperative Immunotherapy: An Expert Clinical Debate
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease · with University Hospital Cologne, Trinity St James's Cancer Institute, University of Turin +1 more
Lung & thoracic cancers
Satellite
Sun Oct 25
14:05–14:25
Looking To the Future: How Emerging Strategies Could Address Unmet Needs in NSCLC
BeOne Medicines - Data, Debate, and New Directions in the NSCLC Continuum:​From Early-Stage Immunotherapy to New Modalities in Advanced Disease
Lung & thoracic cancers
Talk
Sun Oct 25
15:25–15:45
Toxicities of cytokines and intratumoral immunotherapies
Toxicities of immunotherapies beyond immune checkpoints
Nursing & supportive care
Chair
Sun Oct 25
18:30–20:00
Talk
Sun Oct 25
19:25–19:45
Ongoing research and horizon scanning in cancer with ROS1 rearrangements
ESMO Colloquium supported by Eisai - ROS1-rearranged non-small cell lung cancer: Insights in biology, testing and patient management
Lung & thoracic cancers
Talk
Mon Oct 26
09:30–09:50
Finding new applications of diagnostic technologies
YO Forum: Thinking beyond traditional research ideas
Poster
Mon Oct 26
12:00–12:45
Epigenomic priming shapes chemoresistant tumor states in high-grade serous ovarian cancer
Monday Poster Display session 1
Gynaecological cancersBiomarkers & precision oncology
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45
Poster
Mon Oct 26
12:00–12:45
ctDNA for early detection of HPV-induced pelvic cancer relapse: A multicentric prospective study
Monday Poster Display session 1
Gastrointestinal cancersGynaecological cancersBiomarkers & precision oncology

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Institut Curie

Tell us what you sell and we’ll find the people at Institut Curie most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction